Strides Pharma Science: Unanticipated De-Growth Across Markets..
Strides reported a weak quarter witnessing a de-growth across revenues of 12% YoY to Rs.688cr during Q1FY22 owing to major sector headwinds such as...
228 Views
US/Institutional business drives earnings
STR's 4QFY21 operational performance was marginally below our estimate. The robust performance in the US/Institutional segment within emerging...
319 Views
India Small Caps: Position for Outperformance Vs Large & Mid Caps
Late Friday evening, the Securities and Exchange Board of IndianÂ
765 Views
Eris Lifesciences Ltd - Q4FY18 Beats Expectations, FY19E on Track
Eris Lifesciences Limited (ERIS IN) reported Q4FY18 results recently. Performance Highlights Eris reported Q4FY18 consolidated revenues at Rs 2.1...
210 Views
ERIS Lifesciences Limited – Acquisition Led Growth Story
Eris Lifesciences Limited (ERIS IN)Â is engaged in the marketing and manufacturing of branded generic drugs and derives all its revenues from the...
382 Views